Focused On-demand Library for High affinity copper uptake protein 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

Copper transporter 1; Solute carrier family 31 member 1

Alternative UPACC:

O15431; A8K8Z6; Q53GR5; Q5T1M4


High affinity copper uptake protein 1, also known as Copper transporter 1 (SLC31A1), plays a pivotal role in copper homeostasis. It facilitates the transport of copper(1+) across the plasma membrane, directly influencing intracellular copper levels. This protein also engages in the transport of other metals such as silver(1+) and cadmium(2+), and participates in copper(2+) acquisition, showcasing its versatility in metal ion transport. Additionally, SLC31A1 acts as a redox sensor, promoting angiogenesis independently of its copper transport function.

Therapeutic significance:

SLC31A1's dysfunction is linked to neurodegeneration and seizures due to copper transport defect, a severe autosomal recessive disorder. Understanding the role of High affinity copper uptake protein 1 could open doors to potential therapeutic strategies, especially in targeting copper metabolism disorders and enhancing drug delivery for chemotherapeutic agents.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.